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Central nervous system tissue in vivo is composed of a wide heterogeneity of cell types, 
such as neurons, glia, and vascular endothelium. One experimental approach that is 
commonly used to circumvent the inherent problems encountered in studying neuronal 
phenomena is the use of cloned nerve cells such as have been derived from the C- 
1300 murine neuroblastoma. One clone, designated N1E-115, has been extensively 
characterized both biochemically and electrophysiologically, and represents a widely 
used cell culture system for neurobiological studies.' Inasmuch as cloned cells con- 
stitute a population of neurons derived from a single cell, specific questions can be 
addressed to a single aspect of neuronal function. 
Neurotransmitter Receptor-Mediated Cyclic GMP Synthesis 
Clone N1E-115 cells have been shown to possess functional muscarinic and his- 
tamine HI receptors that, when activated, cause a rapid and marked increase in the 
intracellular concentration of cyclic guanosine monophosphate (GMP)Z4 The molec- 
ular hypothesis for receptor-mediated cyclic GMP formation that researchers have 
held for the past several years involves calcium channel activation as the effector that 
couples receptor activation to cyclic GMP f~rmation.~ This hypothesis results primarily 
from the observations that extracellular calcium ions (Ca2+) are necessary for receptor 
responses, and that Ca2' ionophores (such as A23187 or X537A) can cause cyclic 
GMP formation. 
In the course of investigating the molecular mechanism of neuronal activation, we 
gathered direct evidence indicating that a large Ca2+ influx did not occur as a result 
of neurotransmitter agonist stimulation.6 Instead, results were obtained suggesting that 
neurotransmitter agonists may be coupled to guanylate cyclase (the enzyme that 
synthesizes cyclic GMP from guanosine triphosphate (GTP) by involvement of phos- 
pholipase A, and the release of arachidonic acid metabolites: Phospholipase A, is the 
'This work was supported by USPHS Grant NS 20920. 
bPresent address: T Cell Sciences, Inc., 840 Memorial Dr., Cambridge, MA 02139. 
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enzyme that catalyzes the release of arachidonic acid from the & position of membrane 
phospholipids. Thrombin is a serine protease and is the central regulatory enzyme in 
hemostasis. Among the major biological effects of thrombin in causing coagulation of 
blood are cleavage of fibrinopeptide A to convert fibrinogen into clotable fibrin and 
stimulation of platelet degranulation and aggregation. Moreover, thrombin stimulation 
of platelets is known to result in the activation of phospholipase 4 and cause the 
release of arachidonic 
Thrombin Effets on Neuroblastoma Cells 
To explore further the possible involvement of phospholipase A' and arachidonic 
acid release in neurotransmitter action, we tested the ability of thrombin to stimulate 
cyclic GMP formation in intact N1E-115 cells. Thrombin incubation with intact 
neuroblastoma cells caused a marked Ca2+-dependent elevation in cyclic GMP levels 
with a peak around 30-60 seconds7 The time course and Ca2+ dependency of the 
thrombin-induced cyclic GMP response was virtually identical with other neurotrans- 
mitter agonists, such as carbachol and histamine, which stimulate cyclic GMP for- 
mation~.'.~ The EC,, (median effective concentration) for the thrombin response ranged 
from 0.08-0.44 NIH units/ml, which averaged 1.0-1.5 nM, and the cyclic GMP 
levels increased by 4.1 to 19-fold over basal levels measured in intact cells.' 
We sought to establish that this effect was specific for thrombin and to determine 
if receptors for this protease existed on nerve cells. Trypsin, which is another serine 
protease, but with a broad specificity, was about 100-fold less potent and less effective 
in stimulating the cyclic GMP response as compared with a-thrombin. Moreover, 
thrombin treated with diisopropylphosphofluoridate, to inactivate the enzymatic site, 
was 300- to 500-fold less potent as compared with thrombin? Thus, it is likely that 
the enzymatic activity of thrombin is involved in the cyclic GMP response of neu- 
roblastoma cells. Thrombin antagonists also were evaluated for effects in this exper- 
imental preparation. Hirudin, a specific thrombin antagonist isolated from the leech 
salivary gland, inhibited cyclic GMP formation in approximately 1 : 1 stoichiometry, 
and a competitive inhibitor of thrombin, termed DAPA (dansylarginine-N-(3-ethyl- 
1,5-pentanediyl) amide) produced a shift to the right in the thrombin concentration 
cyclic GMP response and yielded a K, value of 17 nM.7 
Thrombin binding to intact neuroblastoma cells studied using [1*'I]thrombin in a 
radioligand binding assay, are characterized as high-affinity receptors with a & (equi- 
librium dissociation constant) of 1.4 nM that number approximately 30 OOO per cell? 
In addition, low-affinity binding with a very high capacity was also found. We believe 
that the high-affinity binding site (Kd = 1.4 nM) is the functional receptor coupled 
to the cyclic GMP response (EC, = 1.2 nM). Mareover, ["'I]thrombin also binds 
to human brain and spinal cord homogenates,"' suggesting that our findings in neu- 
roblastoma cells are not artifactual but, in fact, may represent an aspect of normal 
or pathological neuronal physiology. 
Signijcance and Clinical Implications 
It is unlikely that under normal conditions blood-born clotting factors ever come 
into direct contact with nerve cells in the brain. The possibility exists, however, that 
one or more proteases with thrombin-like specificity might be synthesized by neurons, 
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released, and cause activation of other neurons (i.e., a neuromodulatory function). A 
point of greater interest concerns the function that thrombin interaction may play in 
the neuropathology subsequent to cerebrovascular accidents, head trauma, or similar 
events in which the blood comes into direct contact with the brain. 
Trauma to the central nervous system such as following cerebrovascular hemor- 
rhage and concussive or projectile head injury clearly results in a compromised blood- 
brain barrier. Consequently, nerve cells are directly exposed to blood-borne factors. 
The resultant in vivo situation is profoundly complex and, for that reason, it has been 
difficult to ask questions designed to provide discrete answers concerning the neuronal 
pathophysiology involved in the injury and healing process. 
An extremely exciting possibility concerns whether thrombin may possess mito- 
genic activity in nerve cells. As stated above, little is known about the neuronal cellular 
pathophysiology following stroke or traumatic nervous system injury. If thrombin is 
capable of stimulating differentiated neurons, as we have shown, neurons surviving 
the initial traumatic event may be induced to restore functional synaptic contacts. 
These processes may, in part, underlie a regenerative function that occurs with time 
following a cerebrovascular accident. 
A New Hypothesis of Neurotransmitter Receptor-Mediated Cyclic GMP 
Formation 
The Caz+ dependency and time course of thrombin's activation of neuroblastoma 
cells is similar to that of muscarinic or histaminergic stimulation. Moreover, the 
receptor-mediated biochemical effects of thrombin in causing platelet activation are 
well characterized and involve activation of phospholipase Az and release of arachi- 
donic acid.",'* Interestingly, phospholipase A2 activity is the rate-limiting step in the 
generation of free arachidonic acid, and it is known to be a highly Ca2+-dependent 
enzyme. Released arachidonic acid can undergo oxidative metabolism by way of the 
cyclooxygenase or lipoxygenase pathways to form the prostaglandins or the hydrox- 
yeicosatetraynoic acids, respectively. 
Pharmacologic studies were carried out to evaluate the involvement of phospho- 
lipase A, and arachidonic acid metabolites in cyclic GMP formation. Inhibition of 
phospholipase Az with quinacrine resulted in a concentration-dependent attenuation 
of receptor-mediated cyclic GMP formation. Quinacrine was effective in blocking the 
response elicited by thrombin, carbachol, and histamine with nearly equal potency?' 
This observation suggests that all the above agents that cause a receptor-mediated 
cyclic GMP response do so by the same mechanism. We conducted experiments to 
examine whether quinacrine inhibited the cyclic GMP response to receptor agonists 
in a nonspecific manner. Quinacrine did not inhibit the cyclic GMP response caused 
by sodium nitroprusside (a guanylate cyclase stimulant) at concentrations that totally 
blocked receptor responses. 
Involvement of arachidonic acid metabolites in cyclic GMP formation was also 
investigated. Indomethacin, a drug that inhibits cyclooxygenase and formation of 
prostaglandins, did not inhibit the receptor-mediated response!.* In fact, in many 
experiments, indomethacin actually potentiated by 10-40% the cyclic GMP levels 
measured in response to agonist stimulation. Inhibition of the lipoxygenase pathway 
of arachidonate metabolism with nordihydroguaiaretic acid (NDGA) or eicosatetray- 
noic acid (ETYA) blocked receptor-mediated cyclic GMP synthesis in a concentration- 
dependent manner. As was observed with quinacrine, the responses evoked by throm- 
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bin, carbachol, and histamine were affected similarly by NDGA or ETYA. We believe 
this observation also supports the hypothesis that neurotransmitter receptors couple 
to their respective cyclic GMP responses by a similar molecular mechanism. 
Based on the observations detailed above, we have proposed a new hypothesis for 
the molecular mechanism of neurotransmitter receptor-mediated cyclic GMP for- 
mation.6 We believe this scheme of molecular events following receptor activation and 
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